Polysaccharide-Based Hydrogel Scaffolds in Tissue Engineering: 2025 Market Dynamics, Breakthroughs, and the Road to Next-Gen Regenerative Medicine. Explore How These Biomaterials Are Shaping the Future of Healthcare Innovation.

• Executive Summary: 2025 Market Outlook and Key Trends
• Polysaccharide Hydrogel Scaffold Fundamentals: Materials and Mechanisms
• Current Market Size, Segmentation, and 2025 Forecasts
• Key Players and Strategic Initiatives (e.g., regenemed.com, gelita.com, biotimeinc.com)
• Emerging Technologies: Smart Hydrogels, 3D Bioprinting, and Customization
• Clinical Applications: Orthopedics, Wound Healing, and Organ Regeneration
• Regulatory Landscape and Industry Standards (e.g., fda.gov, iso.org)
• Supply Chain, Manufacturing Innovations, and Sustainability
• Market Drivers, Challenges, and Competitive Analysis
• Future Outlook: Growth Projections (2025–2030), Investment Hotspots, and Disruptive Opportunities (Estimated CAGR: 13–16%)
• Sources & References

Executive Summary: 2025 Market Outlook and Key Trends

The market for polysaccharide-based hydrogel scaffolds in tissue engineering is poised for significant growth in 2025, driven by advances in biomaterials science, increasing demand for regenerative medicine, and ongoing collaborations between academic institutions and industry leaders. Polysaccharides such as alginate, chitosan, hyaluronic acid, and cellulose derivatives are at the forefront due to their biocompatibility, tunable mechanical properties, and ability to mimic the extracellular matrix. These materials are being engineered into hydrogels that support cell proliferation, differentiation, and tissue regeneration, addressing critical needs in orthopedics, wound healing, and organ repair.

Key industry players are expanding their portfolios and production capacities to meet rising demand. Lifecore Biomedical is a prominent supplier of pharmaceutical-grade hyaluronic acid, which is widely used in hydrogel scaffold formulations for cartilage and soft tissue engineering. Merck KGaA (operating as MilliporeSigma in the US) and Thermo Fisher Scientific provide a broad range of research-grade polysaccharides and hydrogel kits, supporting both R&D and preclinical manufacturing. GELITA AG and Ashland Global Holdings are also notable for their production of specialty biopolymers and cellulose derivatives, which are increasingly incorporated into advanced scaffold designs.

Recent years have seen a surge in the adoption of 3D bioprinting and injectable hydrogel technologies, enabling the fabrication of patient-specific scaffolds with controlled architecture and bioactivity. Companies such as CELLINK (a BICO company) are commercializing bioinks based on polysaccharide hydrogels, facilitating the translation of laboratory breakthroughs into clinical and industrial applications. The integration of growth factors, peptides, and nanoparticles into these hydrogels is further enhancing their therapeutic potential, with several preclinical and early clinical studies underway.

Regulatory agencies are increasingly providing guidance for the approval of hydrogel-based medical devices, streamlining the pathway for commercialization. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both issued frameworks for the evaluation of biomaterial safety and efficacy, which is expected to accelerate market entry for innovative scaffold products in 2025 and beyond.

Looking ahead, the polysaccharide-based hydrogel scaffold sector is expected to benefit from continued investment in regenerative medicine, strategic partnerships between material suppliers and device manufacturers, and the growing emphasis on personalized healthcare solutions. As the technology matures, the market is likely to see the emergence of off-the-shelf and custom-designed scaffolds for a broadening range of tissue engineering applications, positioning polysaccharide hydrogels as a cornerstone of next-generation biomedical solutions.

Polysaccharide Hydrogel Scaffold Fundamentals: Materials and Mechanisms

Polysaccharide-based hydrogel scaffolds have emerged as a cornerstone in the field of tissue engineering, owing to their biocompatibility, tunable physical properties, and ability to mimic the extracellular matrix (ECM). These hydrogels are primarily constructed from naturally derived polysaccharides such as alginate, chitosan, hyaluronic acid, cellulose, and dextran. Each of these materials offers unique advantages: for example, alginate, sourced from brown seaweed, is prized for its gentle gelation with divalent cations, while chitosan, derived from chitin, provides inherent antimicrobial properties and supports cell adhesion.

The fundamental mechanism underlying polysaccharide hydrogel formation involves physical or chemical crosslinking of polymer chains, resulting in a three-dimensional, water-swollen network. Physical crosslinking methods, such as ionic gelation (e.g., alginate with calcium ions), are favored for their mild conditions, which preserve cell viability during encapsulation. Chemical crosslinking, using agents like genipin or carbodiimide, enables the creation of more robust and stable scaffolds, suitable for load-bearing applications. Recent advances in 2025 have focused on hybrid crosslinking strategies, combining both physical and chemical methods to fine-tune mechanical strength and degradation rates, critical for matching the requirements of specific tissues.

Material selection and scaffold design are increasingly informed by the intended tissue application. For instance, hyaluronic acid-based hydrogels are widely used for cartilage and soft tissue engineering due to their viscoelasticity and role in native ECM, while cellulose-based hydrogels are gaining traction for bone and nerve regeneration because of their mechanical robustness and modifiability. Companies such as Lonza Group and Cytiva (formerly GE Healthcare Life Sciences) are actively supplying high-purity polysaccharides and hydrogel precursors to research and clinical markets, supporting the development of next-generation scaffolds.

Mechanistically, the interaction between cells and polysaccharide hydrogels is mediated by the scaffold’s porosity, surface chemistry, and degradation profile. These factors govern cell infiltration, nutrient diffusion, and eventual tissue integration. In 2025, there is a notable trend toward the customization of scaffold microarchitecture using advanced fabrication techniques such as 3D bioprinting and microfluidics, enabling precise control over pore size and spatial distribution of bioactive cues. Leading suppliers like Sigma-Aldrich (a subsidiary of Merck KGaA) and Thermo Fisher Scientific provide a broad portfolio of polysaccharide materials and crosslinkers, facilitating rapid prototyping and scale-up of hydrogel scaffolds.

Looking ahead, the next few years are expected to see further integration of bioactive molecules, growth factors, and even living cells into polysaccharide-based hydrogels, enhancing their functionality for regenerative medicine. The convergence of material science, cell biology, and manufacturing innovation positions polysaccharide hydrogel scaffolds as a dynamic and rapidly evolving platform in tissue engineering.

Current Market Size, Segmentation, and 2025 Forecasts

The global market for polysaccharide-based hydrogel scaffolds in tissue engineering is experiencing robust growth, driven by increasing demand for advanced biomaterials in regenerative medicine, wound healing, and 3D cell culture. As of 2025, the market is estimated to be valued in the low hundreds of millions USD, with projections indicating a compound annual growth rate (CAGR) in the high single digits through the next several years. This expansion is fueled by ongoing innovations in scaffold design, biocompatibility, and the integration of smart functionalities such as controlled drug release and bioactive molecule incorporation.

Market segmentation is primarily based on polysaccharide type, application, and end-user. Key polysaccharides utilized include alginate, chitosan, hyaluronic acid, cellulose derivatives, and dextran. Alginate and chitosan hydrogels remain dominant due to their tunable mechanical properties and established safety profiles. Hyaluronic acid-based scaffolds are gaining traction, particularly in cartilage and soft tissue engineering, owing to their intrinsic bioactivity and compatibility with human tissues.

Application-wise, the largest segment is regenerative medicine, encompassing bone, cartilage, and skin tissue engineering. Wound healing and drug delivery are also significant, with polysaccharide hydrogels increasingly used as vehicles for localized, sustained therapeutic release. The research and academic sector continues to be a major end-user, but clinical and commercial adoption is accelerating, especially in North America, Europe, and parts of Asia-Pacific.

Several companies are actively shaping the market landscape. Lonza Group is a prominent supplier of biomaterials, including polysaccharide-based hydrogels for research and clinical applications. Thermo Fisher Scientific offers a range of hydrogel products and cell culture scaffolds, supporting both academic and industrial R&D. Merck KGaA (operating as MilliporeSigma in the US and Canada) provides high-purity polysaccharides and hydrogel kits tailored for tissue engineering. Cytiva (formerly part of GE Healthcare Life Sciences) supplies advanced biomaterials and 3D cell culture platforms, including polysaccharide-based scaffolds. Emerging players and startups are also entering the field, focusing on customization and novel crosslinking chemistries.

Looking ahead, the market is expected to benefit from regulatory approvals of new hydrogel-based medical devices and the expansion of 3D bioprinting applications. The integration of polysaccharide hydrogels with stem cell therapies and personalized medicine approaches is anticipated to further drive demand. As manufacturing processes become more scalable and cost-effective, broader clinical adoption is likely, positioning polysaccharide-based hydrogel scaffolds as a cornerstone of next-generation tissue engineering solutions.

Key Players and Strategic Initiatives (e.g., regenemed.com, gelita.com, biotimeinc.com)

The landscape of polysaccharide-based hydrogel scaffolds for tissue engineering in 2025 is shaped by a dynamic interplay of established biomaterials manufacturers, innovative biotech firms, and strategic collaborations with research institutions. Key players are leveraging advances in material science, bioprinting, and regenerative medicine to expand the clinical and commercial potential of these scaffolds.

Among the most prominent companies, GELITA AG stands out as a global leader in collagen and gelatin biomaterials, with a growing portfolio that includes polysaccharide-based hydrogels. GELITA’s expertise in biopolymer processing and its established supply chain position it as a preferred partner for medical device manufacturers seeking high-purity, customizable hydrogel matrices. The company’s ongoing investments in R&D and partnerships with academic centers are expected to yield new scaffold formulations optimized for cell compatibility and controlled degradation, addressing key requirements in tissue engineering.

Another notable player, BioTime, Inc. (now operating as Lineage Cell Therapeutics), has a strong focus on regenerative medicine and cell-based therapies. The company’s proprietary hydrogel technologies, which incorporate polysaccharides such as alginate and hyaluronic acid, are being developed for applications ranging from cartilage repair to neural tissue regeneration. BioTime’s strategic collaborations with clinical research organizations and medical device firms are anticipated to accelerate the translation of these scaffolds from preclinical studies to human trials in the coming years.

Emerging companies like Regenemed, Inc. are also making significant strides. Regenemed specializes in advanced tissue engineering platforms, including polysaccharide-based hydrogels tailored for 3D cell culture and organoid development. Their modular scaffold systems are designed to mimic native extracellular matrices, supporting cell proliferation and differentiation for a variety of tissue types. The company’s partnerships with biotechnology firms and research hospitals are expected to drive innovation in scaffold customization and scalability.

Looking ahead, the sector is witnessing increased interest from major biomaterials suppliers such as Sigma-Aldrich (a subsidiary of Merck KGaA), which offers a broad range of polysaccharides and hydrogel precursors for research and clinical use. Sigma-Aldrich’s global distribution network and technical support services are facilitating the adoption of advanced hydrogel scaffolds in both academic and industrial settings.

Strategic initiatives across the industry include joint ventures to develop next-generation bioinks for 3D bioprinting, licensing agreements for proprietary hydrogel formulations, and investments in automated manufacturing technologies. These efforts are expected to enhance the reproducibility, scalability, and regulatory compliance of polysaccharide-based hydrogel scaffolds, positioning them as a cornerstone of future tissue engineering solutions.

Emerging Technologies: Smart Hydrogels, 3D Bioprinting, and Customization

The landscape of polysaccharide-based hydrogel scaffolds for tissue engineering is rapidly evolving, with 2025 poised to be a pivotal year for the integration of emerging technologies such as smart hydrogels, 3D bioprinting, and advanced customization. These innovations are driving the field toward more functional, patient-specific, and clinically translatable solutions.

Smart hydrogels, which respond to environmental stimuli such as pH, temperature, or biochemical signals, are gaining traction for their ability to mimic dynamic tissue environments. In 2025, research and development efforts are focusing on incorporating bioactive cues and controlled drug delivery capabilities into polysaccharide-based matrices. Companies like Cytiva (formerly GE Healthcare Life Sciences) and Sigma-Aldrich (now part of Merck KGaA) are supplying high-purity alginate, chitosan, and hyaluronic acid derivatives, which serve as foundational materials for these smart systems. These materials are being engineered to enable on-demand release of growth factors or therapeutic agents, enhancing tissue regeneration and integration.

3D bioprinting is another transformative technology, enabling the fabrication of complex, patient-specific scaffolds with precise control over architecture and composition. In 2025, polysaccharide-based bioinks are being optimized for printability, cell viability, and mechanical performance. CELLINK, a leader in bioprinting platforms, offers a range of polysaccharide-based bioinks tailored for various tissue engineering applications, including cartilage, skin, and vascular tissues. Their systems allow for the integration of living cells and bioactive molecules directly into the printed constructs, accelerating the translation from bench to bedside.

Customization is increasingly central to scaffold design, with digital modeling and patient imaging data enabling the creation of bespoke implants. Companies such as 3D Systems are advancing software and hardware solutions that facilitate the conversion of medical imaging into printable scaffold geometries. This approach supports the production of implants that closely match patient anatomy, improving functional outcomes and reducing the risk of rejection.

Looking ahead, the convergence of smart hydrogels, 3D bioprinting, and digital customization is expected to yield next-generation tissue engineering scaffolds with enhanced biological performance and clinical applicability. Industry collaborations and partnerships with academic institutions are anticipated to accelerate regulatory approvals and commercialization. As polysaccharide-based hydrogels continue to demonstrate biocompatibility and tunable properties, their adoption in regenerative medicine and personalized healthcare is set to expand significantly in the coming years.

Clinical Applications: Orthopedics, Wound Healing, and Organ Regeneration

Polysaccharide-based hydrogel scaffolds are increasingly at the forefront of clinical applications in tissue engineering, particularly in orthopedics, wound healing, and organ regeneration. As of 2025, these biomaterials are being actively developed and evaluated for their biocompatibility, tunable mechanical properties, and ability to mimic the extracellular matrix, which are critical for supporting cell proliferation and tissue integration.

In orthopedics, polysaccharide hydrogels such as those derived from alginate, chitosan, and hyaluronic acid are being utilized for cartilage and bone regeneration. Companies like GELITA AG and DuPont are advancing the development of medical-grade hydrogels, with ongoing collaborations with clinical research centers to optimize scaffold formulations for load-bearing applications. Recent clinical trials are focusing on injectable hydrogel systems that can deliver stem cells or growth factors directly to defect sites, aiming to accelerate bone healing and reduce recovery times.

Wound healing is another area where polysaccharide-based hydrogels are demonstrating significant clinical impact. Hydrogels composed of chitosan and alginate are being commercialized for their inherent antimicrobial properties and ability to maintain a moist wound environment, which is essential for optimal healing. ConvaTec Group and Smith & Nephew are among the leading manufacturers offering advanced wound dressings that incorporate polysaccharide hydrogels. These products are being adopted in hospitals and outpatient settings for the management of chronic wounds, burns, and diabetic ulcers, with ongoing post-market surveillance to assess long-term outcomes.

In the realm of organ regeneration, polysaccharide-based scaffolds are being engineered to support the growth and differentiation of various cell types, including hepatocytes and pancreatic islets. Research partnerships between biotechnology firms and academic institutions are accelerating the translation of these scaffolds from bench to bedside. For example, Evonik Industries is investing in the development of customizable hydrogel platforms for 3D bioprinting of organoids and tissue constructs, with the goal of addressing the shortage of transplantable organs. Early-stage clinical studies are underway to evaluate the safety and efficacy of these constructs in preclinical models, with human trials anticipated in the next few years.

Looking ahead, the clinical adoption of polysaccharide-based hydrogel scaffolds is expected to expand, driven by advances in material science, regulatory approvals, and the growing demand for regenerative therapies. The integration of smart functionalities—such as controlled drug release and real-time monitoring—into hydrogel systems is poised to further enhance their therapeutic potential across orthopedic, wound healing, and organ regeneration applications.

Regulatory Landscape and Industry Standards (e.g., fda.gov, iso.org)

The regulatory landscape for polysaccharide-based hydrogel scaffolds in tissue engineering is evolving rapidly as these biomaterials transition from research laboratories to clinical and commercial applications. In 2025, the U.S. Food and Drug Administration (U.S. Food and Drug Administration) continues to play a central role in the oversight of medical devices, including hydrogel scaffolds intended for tissue repair, regeneration, or as drug delivery matrices. These products are typically regulated under the Center for Devices and Radiological Health (CDRH) and are classified based on their intended use and risk profile, often falling under Class II or Class III medical devices. The FDA’s 510(k) premarket notification pathway remains the most common route for devices demonstrating substantial equivalence to existing products, while novel scaffolds with unique features or claims may require the more rigorous Premarket Approval (PMA) process.

In parallel, international standards are being harmonized to facilitate global market access. The International Organization for Standardization (International Organization for Standardization) has established several relevant standards, such as ISO 10993 for biological evaluation of medical devices, which is critical for demonstrating the biocompatibility of polysaccharide-based hydrogels. ISO 13485, which specifies requirements for a quality management system for medical device manufacturers, is increasingly adopted by companies seeking to ensure compliance and streamline regulatory submissions across multiple jurisdictions.

Recent years have seen increased collaboration between regulatory agencies and industry stakeholders to address the unique challenges posed by advanced biomaterials. For example, the FDA’s Tissue Reference Group and the Regenerative Medicine Advanced Therapy (RMAT) designation provide pathways for expedited review and guidance for innovative tissue engineering products. In 2025, regulatory bodies are placing greater emphasis on the characterization of raw materials, traceability, and the reproducibility of hydrogel scaffold manufacturing processes. This is particularly relevant for polysaccharide-based scaffolds, where batch-to-batch variability and source material purity can impact safety and efficacy.

Industry leaders such as Cytiva (formerly GE Healthcare Life Sciences), Sigma-Aldrich (now part of Merck KGaA), and Thermo Fisher Scientific are actively engaged in developing and supplying high-purity polysaccharides and hydrogel precursors, often adhering to Good Manufacturing Practice (GMP) standards. These companies are also involved in shaping best practices and contributing to standardization efforts through industry consortia and technical committees.

Looking ahead, the regulatory environment is expected to become more adaptive, with ongoing updates to guidance documents and standards reflecting advances in scaffold design, functionalization, and clinical application. The convergence of regulatory requirements and industry standards will be crucial for accelerating the safe and effective translation of polysaccharide-based hydrogel scaffolds from bench to bedside in the coming years.

Supply Chain, Manufacturing Innovations, and Sustainability

The supply chain and manufacturing landscape for polysaccharide-based hydrogel scaffolds in tissue engineering is undergoing significant transformation in 2025, driven by advances in bioprocessing, automation, and sustainability imperatives. Polysaccharides such as alginate, chitosan, hyaluronic acid, and cellulose derivatives are increasingly sourced from both traditional and engineered biological systems, with a growing emphasis on traceability and environmental impact. Major suppliers of pharmaceutical-grade polysaccharides, including DSM and Danisco (a DuPont Nutrition & Health brand), have expanded their portfolios to include highly purified, customizable biopolymers tailored for medical and tissue engineering applications.

Manufacturing innovations in 2025 are centered on scalable, reproducible hydrogel fabrication methods. Companies such as Evonik Industries and Lonza Group are investing in automated, closed-system production lines that minimize contamination risk and ensure batch-to-batch consistency. 3D bioprinting is increasingly integrated into scaffold manufacturing, enabling precise control over pore architecture and mechanical properties. CELLINK, a leader in bioprinting technology, has developed proprietary printheads and bioink formulations specifically optimized for polysaccharide-based hydrogels, facilitating the production of complex, patient-specific scaffolds.

Sustainability is a key driver in the sector, with manufacturers adopting green chemistry principles and circular economy models. For instance, Novozymes is leveraging enzymatic processes to extract and modify polysaccharides with reduced energy and solvent use, while Sigma-Aldrich (now part of Merck KGaA) offers biodegradable hydrogel precursors and supports take-back programs for laboratory plastics. There is also a trend toward utilizing waste streams from the food and agricultural industries as feedstocks for polysaccharide extraction, reducing reliance on virgin resources and lowering the carbon footprint of scaffold production.

Looking ahead, the next few years are expected to see further integration of digital supply chain management tools, such as blockchain-based traceability and real-time quality monitoring, to enhance transparency and regulatory compliance. Strategic partnerships between biomaterial suppliers, contract manufacturers, and tissue engineering firms are anticipated to accelerate the commercialization of next-generation hydrogel scaffolds. As regulatory frameworks evolve to support advanced therapies, the sector is poised for robust growth, with sustainability and manufacturing innovation at its core.

Market Drivers, Challenges, and Competitive Analysis

The market for polysaccharide-based hydrogel scaffolds in tissue engineering is experiencing robust momentum in 2025, driven by a convergence of technological, clinical, and regulatory factors. The increasing prevalence of chronic diseases, rising demand for regenerative medicine, and a global focus on advanced wound care are key drivers. Polysaccharide hydrogels—derived from natural sources such as alginate, chitosan, hyaluronic acid, and cellulose—are favored for their biocompatibility, tunable mechanical properties, and ability to mimic the extracellular matrix, making them highly attractive for tissue engineering applications.

Major medical device and biomaterials companies are intensifying their R&D investments in this sector. Evonik Industries, a global leader in specialty chemicals, has expanded its biomaterials portfolio to include advanced hydrogel systems, emphasizing polysaccharide-based solutions for cell encapsulation and tissue scaffolding. DSM (now part of dsm-firmenich), with its longstanding expertise in biomedical materials, continues to develop and supply medical-grade polysaccharides for hydrogel fabrication, supporting both research and commercial-scale tissue engineering projects. GELITA, known for its collagen and gelatin products, is also exploring hybrid hydrogel systems that incorporate polysaccharides to enhance scaffold performance.

The competitive landscape is further shaped by the entry of specialized biotech firms and startups. Companies such as Advanced BioMatrix and Sigma-Aldrich (a subsidiary of Merck KGaA) supply a wide range of polysaccharide-based hydrogel kits and raw materials, catering to both academic and industrial tissue engineering labs. These suppliers are focusing on customizable formulations, sterility, and scalability to meet the evolving needs of regenerative medicine.

Despite these advances, several challenges persist. Batch-to-batch variability in natural polysaccharide sources, regulatory complexities for clinical translation, and the need for scalable, reproducible manufacturing processes remain significant hurdles. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are actively updating guidelines for biomaterial-based medical devices, which is expected to streamline approval pathways but also raise the bar for quality and documentation.

Looking ahead, the next few years are likely to see increased collaboration between material suppliers, device manufacturers, and clinical research organizations. Advances in 3D bioprinting and biofabrication, coupled with the integration of smart and stimuli-responsive polysaccharide hydrogels, are poised to expand the application scope. As the competitive field matures, companies with strong IP portfolios, robust supply chains, and regulatory expertise—such as Evonik Industries and DSM—are expected to maintain leadership, while innovative startups drive niche applications and customization.

Future Outlook: Growth Projections (2025–2030), Investment Hotspots, and Disruptive Opportunities (Estimated CAGR: 13–16%)

The global market for polysaccharide-based hydrogel scaffolds in tissue engineering is poised for robust expansion between 2025 and 2030, with industry analysts and sector participants projecting a compound annual growth rate (CAGR) in the range of 13–16%. This growth is underpinned by accelerating demand for advanced biomaterials in regenerative medicine, wound healing, and organ repair, as well as the increasing adoption of sustainable, biocompatible materials in clinical and research settings.

Key investment hotspots are emerging in North America, Europe, and East Asia, where strong biomedical research infrastructure and supportive regulatory environments are catalyzing innovation. The United States remains a central hub, with companies such as Thermo Fisher Scientific and Corning Incorporated actively expanding their portfolios of hydrogel-based products for cell culture and tissue engineering. In Europe, Germany and the Netherlands are notable for their concentration of biomaterials startups and established players, including Evonik Industries, which is investing in next-generation bioresorbable polymers and hydrogel technologies.

Asia-Pacific is expected to witness the fastest growth, driven by increasing healthcare investments and government-backed R&D initiatives. In Japan, Fujifilm Holdings Corporation is leveraging its expertise in regenerative medicine and biomaterials, while in China, companies such as GENEWIZ (a part of Azenta Life Sciences) are expanding their capabilities in tissue engineering solutions.

Disruptive opportunities are anticipated in the development of “smart” hydrogels—materials that respond to physiological stimuli such as pH, temperature, or enzymatic activity. These innovations are expected to enable more precise control over cell behavior and tissue regeneration, opening new avenues for personalized medicine and complex organ reconstruction. Additionally, the integration of 3D bioprinting with polysaccharide-based hydrogels is gaining momentum, with companies like CELLINK (a BICO company) pioneering bioink formulations that facilitate the fabrication of functional tissue constructs.

Looking ahead, strategic collaborations between material suppliers, biotechnology firms, and clinical research organizations are likely to accelerate commercialization. The sector’s outlook is further strengthened by increasing regulatory approvals for hydrogel-based medical devices and a growing pipeline of clinical trials evaluating their efficacy in diverse therapeutic areas. As sustainability and biocompatibility remain top priorities, polysaccharide-based hydrogel scaffolds are well-positioned to capture a significant share of the tissue engineering market through 2030 and beyond.

Sources & References

• Lifecore Biomedical
• Thermo Fisher Scientific
• GELITA AG
• CELLINK
• 3D Systems
• DuPont
• ConvaTec Group
• Smith & Nephew
• Evonik Industries
• International Organization for Standardization
• DSM
• EMA
• Fujifilm Holdings Corporation